federal_register: 2023-11899

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2023-11899 Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment; Revised Draft Guidance for Industry; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment." This draft guidance is intended to revise and replace the current draft guidance for industry entitled "Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Establishing Effectiveness of Drugs for Treatment" issued on December 5, 2019. This draft guidance provides recommendations for drug development programs for drugs intended to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS). 2023-06-05 2023 6 https://www.federalregister.gov/documents/2023/06/05/2023-11899/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-for-treatment https://www.govinfo.gov/content/pkg/FR-2023-06-05/pdf/2023-11899.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment." This draft guidance...  

Links from other tables